Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Morton

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Nature Protocols|April 5, 2007
Establishment of human tumor xenografts in immunodeficient miceChristopher L Morton, Peter J Houghton
Current Protocols in Pharmacology|September 28, 2011
Preclinical chemotherapeutic tumor models of common childhood cancers: solid tumors, acute lymphoblastic leukemia, and disseminated neuroblastomaChristopher L Morton, Rachel A Papa, Richard B Lock, et al.
Nature Structural Biology|April 8, 2003
Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzymeSompop Bencharit, Christopher L Morton, Yu Xue, et al.
Biochemistry|February 18, 2004
Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a modelMonika Wierdl, Christopher L Morton, Nathan K Nguyen, et al.
Pediatric Blood & Cancer|December 13, 2006
SK-NEP-1 and Rh1 are Ewing family tumor linesMalcolm A Smith, Christopher L Morton, Doris Phelps, et al.
Cancer Drug Resistance (Alhambra, Calif.)|April 22, 2022
Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcomaSamson Ghilu, Christopher L Morton, Angelina V Vaseva, et al.
Bioorganic & Medicinal Chemistry|July 3, 2003
Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolismKyoung Jin P Yoon, Christopher L Morton, Philip M Potter, et al.
Cancer Research|October 1, 2009
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcomaRaushan T Kurmasheva, Lorina Dudkin, Catherine Billups, et al.
Pediatric Blood & Cancer|May 22, 2008
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing programStephen T Keir, Christopher L Morton, Catherine Billups, et al.
Pediatric Blood & Cancer|October 6, 2010
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testingMin H Kang, Malcolm A Smith, Christopher L Morton, et al.
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Nature Protocols|April 5, 2007
Establishment of human tumor xenografts in immunodeficient miceChristopher L Morton, Peter J Houghton
Current Protocols in Pharmacology|September 28, 2011
Preclinical chemotherapeutic tumor models of common childhood cancers: solid tumors, acute lymphoblastic leukemia, and disseminated neuroblastomaChristopher L Morton, Rachel A Papa, Richard B Lock, et al.
Nature Structural Biology|April 8, 2003
Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzymeSompop Bencharit, Christopher L Morton, Yu Xue, et al.
Biochemistry|February 18, 2004
Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a modelMonika Wierdl, Christopher L Morton, Nathan K Nguyen, et al.
Pediatric Blood & Cancer|December 13, 2006
SK-NEP-1 and Rh1 are Ewing family tumor linesMalcolm A Smith, Christopher L Morton, Doris Phelps, et al.
Cancer Drug Resistance (Alhambra, Calif.)|April 22, 2022
Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcomaSamson Ghilu, Christopher L Morton, Angelina V Vaseva, et al.
Bioorganic & Medicinal Chemistry|July 3, 2003
Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolismKyoung Jin P Yoon, Christopher L Morton, Philip M Potter, et al.
Cancer Research|October 1, 2009
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcomaRaushan T Kurmasheva, Lorina Dudkin, Catherine Billups, et al.
Pediatric Blood & Cancer|May 22, 2008
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing programStephen T Keir, Christopher L Morton, Catherine Billups, et al.
Pediatric Blood & Cancer|October 6, 2010
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testingMin H Kang, Malcolm A Smith, Christopher L Morton, et al.
Pageof 10